Category: Infused Products & Extracts

Isodiol International Inc. Provides Update on Be Tru Organics, Announces New Distribution Agreement

SHARE THIS POST January 9, 2018 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce Be Trū Organics™ has signed a distribution agreement with United Natural Foods Inc (UNFI), the largest publicly traded wholesale distributor to the natural, organic and specialty industry in the United States and Canada. With their distribution centers in the US and Canada, UNFI excels in the distribution of natural and organic foods and wellness products by fulfilling the highest standards for quality, consistency, product assortments, and dependability.   Specifically, UNFI provides and delivers products for grocery, produce, health and beauty, bakery, and more. “UNFI been recognized as one of America’s best managed companies, and with the continuous growth in the natural product industry, we are very excited about the opportunities this presents for Be Trū,” said CEO of Isodiol, Marcos Agramont.  “UNFI has a very diversified sales base including natural product superstores, conventional supermarket chains, and independent health food retailers, giving consumers plenty of access to Be Trū products.” “UNFI’s track record speaks for itself, and we are very pleased to be moving forward with this distribution agreement,” added Keith Gordon, CEO of Be Trū. “UNFI will be instrumental in introducing this brand to mainstream America and will allow Be...

Read More

MYM Acquires Budly, the “Uber of Cannabis”

SHARE THIS POST Vancouver, B.C., January 5, 2018 – MYM Nutraceuticals Inc. (CSE: MYM) (the “Company” or “MYM”) is pleased to announce that the Company has entered into a binding letter of intent with Budly Software Inc. (“Budly”), a leading software company that has developed a smartphone-enabled sales and distribution system connecting medicinal cannabis patients with local dispensary drivers for fast delivery and monitoring of orders.  Using the system, a customer can select a dispensary, place an order, and then choose a driver to deliver it.  The customer can then track the order on his smartphone and knows exactly when it will arrive.  Orders can be placed via the Budly app on iOS, Android and Windows phones, and via the website “The Budly software is a game-changer for MYM because it brings us one step closer to becoming a fully integrated global cannabis company,” commented Rob Gietl, CEO of MYM. “Budly’s clean and simple interface allows orders to be easily placed by patients, right on their phone, and provides extensive back end management and logistics control for licensed producers and dispensaries.” The Budly system consists of two iOS apps, two Android apps, one web app, a dispensary backend admin and a master admin system.  The system also has advanced features such as GPS tracking of drivers, flexible geo-fencing adjustments for customers, and real-time order confirmations.  MYM intends to...

Read More

Neutrisci Announces A Major R&D MOU With Scientus Pharma To Develop A Medical Cannabinoid Retail Product

SHARE THIS POST Vancouver, British Columbia – January 8, 2018 – NeutriSci International Inc. (the “Company” or “NeutriSci”) (TSX-V: NU) (OTCQB: NRXCF) (FRANKFURT: 1N9), the innovator and pioneer behind neuenergy®, is pleased to announce it has entered into a major R&D Memorandum of Understanding with Scientus Pharma Inc. (“Scientus Pharma”). Under the terms of the MOU, both companies have agreed to share their technologies to develop, test, produce, and distribute a medical cannabinoid product for existing retail distribution networks across Canada. The core ingredients in NeutriSci’s products have significant anti-oxidant properties and health benefits. Scientus Pharma will conduct research on Neutrisci’s products and their components in combination with various cannabinoids. Research activities will initially be funded by Neutrisci. Both companies will have rights for further product development and testing, including potentially preclinical and clinical trials, which may be co-funded. NeutriSci President Mr. Glen Rehman stated, “This Scientus Pharma partnership helps position us at the forefront of developing new and innovative cannabinoid based medical products in Canada. Scientus Pharma, along with its existing partnerships, is sure to be a dominant player in the cannabis space in Canada. Through a collaborative effort, we will incorporate NeutriSci’s IP, technology and ingredients with Scientus’ expertise, proprietary technical know-how, and resources. By leveraging both parties existing partnerships, we will be positioned to offer the national retail consumer a safe, effective, dose controlled product that...

Read More

2017 Wrap-Up by Lexaria’s CEO

SHARE THIS POST Kelowna, British Columbia – January 8, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces it’s been quite an amazing year for Lexaria stakeholders – the busiest and most productive we’ve had. I’ve welcomed so many new shareholders and Lexaria fans in 2017 and I want to ensure both our new followers as well as our long-term supporters remember just how much we’ve achieved in the past year. Financial Improvement In mid-2016 our finances were in rough shape and our balance sheet was weak. I made a promise to everyone back then that Lexaria’s first priority was to ensure we could survive as a strong and independent company. In October 2016 our first patent was granted by the US Patent and Trademark Office (USPTO) and that event – which we had been working on internally, quietly, for two years – changed everything. We’ve raised well over US$4 million in equity since then and paid off all our debt. We never stooped to sign any toxic convertible finance deals; not for a single minute did we forget that our first priority is to our shareholders and our moral and fiduciary duties are to act in the best interest of shareholders. Thus when we completed a brokered private placement early in the Spring of 2017 we did so at prices much closer to...

Read More

Isodiol International Inc. Signs Licensing Agreement With Level Brands Inc And Its Chairman Emeritus And Chief Brand Strategist Kathy Ireland

SHARE THIS POST Isodiol to begin marketing new line of phytoceutical products for kathy ireland® Health & Wellness and Ireland Men One January 8, 2018 – Vancouver, BC – Isodiol International Inc., (CSE: ISOL) (OTC:ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has entered into a licensing agreement with Level Brands Inc. (NYSE: LEVB), an innovative marketing and licensing company that provides bold, unconventional and socially responsible branding for leading businesses. Under the agreement, Isodiol will work with Level Brands to develop consumer products for its subsidiaries, kathy ireland® Health & Wellness and Ireland Men One (I’M1), the company’s lifestyle brand for men.  Encore Endeavor One (EE1), Level Brands’ corporate brand management and producer of experiential entertainment events, will provide strategic advisory services for the new wellness product lines. “We look forward to incorporating Kathy Ireland’s proven genius into Isodiol’s existing product strategy,” says Marcos Agramont, CEO of Isodiol.  “With more than 17,000 diverse offerings in the product line, Kathy Ireland has earned the confidence of millions and we are excited to introduce those consumers to the Isodiol brand.  She will bring tremendous energy into this burgeoning field and we look forward to working with her and the Level Brands’ team to provide safe, consistent, and highly bioactive cannabinoid products to the ever-expanding market.” kathy...

Read More

Creso Pharma Market Update

Highlight Creso completes due diligence for Mernova Medicinal Inc.’s Canadian medicinal cannabis growing facility Construction contract signed, ground works commenced in Canada and project is on track for completion in Q3 2018 Canada amends the Cannabis Act. Bill C-45 to allow edible cannabis products in 2019; opportunities for Creso’s cannaQIX® and cannapeal® product ranges Over 200,000 patients now registered for medicinal cannabis in Canada Nova Scotia opens public consultation on medicinal cannabis Mernova Medicinal and Creso join 16 other licenced producers and Ad Standards group to further self-regulation for the industry Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) is pleased to provide this market update: Due diligence completed for medicinal cannabis growing facility Creso has successfully completed due diligence on the Mernova Medicinal Inc. acquisition, a 20,000 square foot medical cannabis growing facility in Nova Scotia, Canada. Also, the application for a medical cannabis cultivation licence under Health Canada’s Access to Cannabis for Medical Purposes Regulation (ACMPR) program is progressing. It will give Creso a significant competitive advantage as one of the few companies globally and the only medicinal cannabis company listed on the ASX with 100% ownership and capacity to cultivate, extract and manufacture its own innovative cannabis and hemp derived human and animal therapeutic products in Canada. These products will be for local distribution as well as export to countries which accept cannabis and hemp imports....

Read More
  • 1
  • 2